Dabrafenib
Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is N-{3- [5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6- difluorobenzene sulfonamide, methanesulfonate salt. it is used for the treatment of patients with unresectable or metastatic melanoma with braf V600E mutation.
Primary Characteristics
It is of Synthetic origin and belongs to phenylthiazoles.
It belongs to Protein kinase inhibitor pharmacological group on the basis of mechanism of action.
Molecular Weight: 615.68 · Solubility in Water: insoluble · Non-proprietary name: Dabrafenib.
Pharmacokinetics
Absorption: Dabrafenib has an oral bioavailability is 95%.
Distribution: Dabrafenib has a volume of distribution is 70.3L. plasma protein binding is 99.7%.
Elimination: it is metabolised via hepatic, plasma half-life is 8hrs.
Advertisement
Indications
Dabrafenib is primarily indicated in conditions like Metastatic melanoma, Metastatic melanoma.
Contraindications
None recorded.
Dosage
Dabrafenib's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 150 mg | 150 mg | Every 2h | PO | as a single agent |
| 150 mg | 150 mg | Every 2h | PO | in combination with trametinib 2mg once daily |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Dabrafenib is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Arthralgia, Chills, Constipation , Cough , Fatigue, Headache, hyperkeratosis, Myalgia, Nausea, night sweats, palmae plantar erythrodysesthesia syndrome, papilloma, pyrexia, Rash, Vomiting .
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.8.2 — Cytotoxic (anti-neoplastic) drugs